Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Victoria's Secret & Co (VSXY) Price & Performance

Heron Therapeutics IncTrade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Victoria's Secret & Co — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Victoria's Secret & Co trades at $94.16 (market cap $7.48B). The key difference: Victoria's Secret & Co is far larger — about 121.7× Heron Therapeutics Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXVSXY
Market Cap
$61.47M$7.48B
Sector
HealthConsumer Cyclical
52-Week High
$1.49$99.97
52-Week Low
$0.32$21.34
Enterprise Value
$168.21M$10.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $92.97, down 7.0% on the day but maintains strong technical momentum with bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow projections for 2026. Recent news highlights international expansion success, particularly in China, and data-driven marketing initiatives driving growth.

The stock presents a balanced opportunity with analyst consensus favoring Buy ratings (55.6%) and a $91 price target near current levels. Key risks include competitive pressures in apparel retail and margin volatility, while catalysts include continued international growth and potential earnings surprises in Q2 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY